STOCK TITAN

Standard BioTools (LAB) director receives new RSU and stock option awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

STANDARD BIOTOOLS INC. director Carey Thomas D. reported equity compensation grants consisting of restricted stock units and stock options. He received 99,116 RSUs that vest in full on the earlier of June 18, 2027 or one day before the next annual stockholders’ meeting, subject to continued service. Each RSU converts into one share of common stock at vesting. He was also granted stock options for 263,884 shares at an exercise price of $0.8297 per share, vesting in twelve equal monthly installments beginning on July 18, 2026, and expiring on June 18, 2036. Following these awards, he directly holds 344,456 shares of common stock and 263,884 stock options.

Positive

  • None.

Negative

  • None.
Insider Carey Thomas D.
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to buy) 263,884 $0.00 --
Grant/Award Common Stock 99,116 $0.00 --
Holdings After Transaction: Stock Option (Right to buy) — 263,884 shares (Direct, null); Common Stock — 344,456 shares (Direct, null)
Footnotes (1)
  1. Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 18, 2027 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. The Option becomes exercisable in twelve equal monthly installments beginning on July 18, 2026, subject to the Reporting Person's continued service through the applicable vesting date.
RSU grant size 99,116 units Restricted Stock Units vesting by June 18, 2027 or earlier
Option grant size 263,884 shares Stock options linked to common stock, compensation grant
Option exercise price $0.8297 per share Conversion or exercise price for stock option grant
Option expiration June 18, 2036 Expiration date for the stock option award
Post-grant share holdings 344,456 shares Total common shares directly held after RSU grant
Underlying option shares 263,884 shares Common shares underlying the stock option grant
Restricted Stock Units ("RSUs") financial
"Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 18, 2027"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (Right to buy) financial
"Stock Option (Right to buy) with an exercise price of 0.8297 per share"
vest financial
"RSUs that vest in full on the earlier to occur of June 18, 2027"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercise price financial
"conversion_or_exercise_price of 0.8297 per share for the option grant"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date of 2036-06-18T00:00:00.000Z for the stock option"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Carey Thomas D.

(Last)(First)(Middle)
C/O STANDARD BIOTOOLS INC.
50 MILK STREET, 10TH FLOOR

(Street)
BOSTON MASSACHUSETTS 02109

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
STANDARD BIOTOOLS INC. [ LAB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/18/2026A99,116(1)A$0344,456D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to buy)$0.829706/18/2026A263,884 (2)06/18/2036Common Stock263,884$0263,884D
Explanation of Responses:
1. Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 18, 2027 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.
2. The Option becomes exercisable in twelve equal monthly installments beginning on July 18, 2026, subject to the Reporting Person's continued service through the applicable vesting date.
/s/ Thomas D. Carey by Tomone Tanaka, Attorney-in-Fact06/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did LAB director Carey Thomas D. report on this Form 4?

Director Carey Thomas D. reported receiving two equity awards: 99,116 restricted stock units and stock options for 263,884 shares. Both grants are compensation-related and subject to vesting conditions tied to his continued service with Standard BioTools.

How many Standard BioTools (LAB) shares does Carey Thomas D. hold after these grants?

After these grants, Carey Thomas D. directly holds 344,456 shares of Standard BioTools common stock. In addition, he holds stock options covering 263,884 shares, which provide the right to purchase more shares if the vesting and exercise conditions are satisfied.

What are the terms of the RSU grant reported by LAB director Carey Thomas D.?

The RSU grant covers 99,116 units that vest in full on the earlier of June 18, 2027 or one day before Standard BioTools’ next annual stockholders’ meeting. Vesting is conditioned on his continued service, and each vested RSU delivers one share of common stock.

What are the key details of the stock option grant to LAB director Carey Thomas D.?

The stock option grant covers 263,884 shares of common stock at an exercise price of $0.8297 per share. The options vest in twelve equal monthly installments starting July 18, 2026, contingent on continued service, and expire on June 18, 2036 if not exercised.

Are the LAB equity awards to Carey Thomas D. open-market purchases or compensation grants?

The reported transactions are compensation grants, not open-market purchases. The Form 4 uses transaction code A for grant or award, with a zero purchase price, and footnotes describing vesting schedules for RSUs and options based on continued service with Standard BioTools.